Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.

Immunobiology - 1 Feb 2017

Subías Hidalgo Marta, Martin Merinero Hector, López Alicia, Anter Jaouad, García Sheila Pinto, Ataúlfo Gonzalez-Fernández Fernando, Forés Rafael, Lopez-Trascasa Margarita, Villegas Ana, Ojeda Emilio, Rodríguez de Córdoba Santiago

Abstract excerpt

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis that is effectively treated with eculizumab. However, treatment responses are reported heterogeneous with some patients presenting residual hemolysis and requiring RBC transfusions. Recent reports have shown that both extravascular hemolysis and incomplete C5 blockade can explain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement Activation
Share to Complement C3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C5

Share to Complement System Proteins

Share to Cytotoxicity, Immunologic

Share to Hemoglobinuria, Paroxysmal

Share to Hemolysis

Share to Receptors, Complement 3b

Source

Identifiers

PMID: 27644115
DOI: 10.1016/j.imbio.2016.09.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.PMID 27644115Read ↗

Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.Semantic proximity Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitorSemantic proximity Read ↗

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaSemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic StrategiesSemantic proximity Read ↗

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.Semantic proximity Read ↗

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia.Semantic proximity Read ↗

[Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].Semantic proximity Read ↗

Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disordersSemantic proximity Read ↗

Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.